Literature DB >> 23287286

Variations in FEV₁ decline over time in chronic obstructive pulmonary disease and its implications.

Donald P Tashkin1.   

Abstract

PURPOSE OF REVIEW: This article reviews findings from longitudinal observational studies in both general and chronic obstructive pulmonary disease (COPD) populations, as well as from intervention trials in COPD, in which the annual rate of decline in forced expired volume in 1  s (FEV₁) has been measured. The purpose of the review is to describe the individual variability in rates of decline in FEV₁ within these populations, explore the factors contributing to this variability and discuss its implications. RECENT
FINDINGS: Individual rates of decline in FEV₁ have been found to vary considerably across participants with COPD in both observational cohorts and intervention trials from decreases as rapid as 150-200  ml per year to increases of up to approximately 150  ml per year, with mean rates of decline ranging from 33 to 69  ml per year. Aside from technical and biologic (e.g., time of day, season, weather, fatigue) sources of variation, other influential factors have included smoking status (most notably current versus former smoking), baseline smoking intensity, baseline lung function, airway hyperresponsiveness, exacerbation frequency, and, variably, age and sex. The presence of emphysema may also be a determinant, as well as certain biomarkers and gene variants.
SUMMARY: The wide distribution of individual rates of decline in FEV₁ includes especially rapid and slow declines. Future research is needed to identify biomarkers that both are predictive of a rapid decline within individuals who might then be targeted for special intervention and might also serve as surrogate endpoints in interventional trials.

Entities:  

Mesh:

Year:  2013        PMID: 23287286     DOI: 10.1097/MCP.0b013e32835d8ea4

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  13 in total

1.  Environmental exposures and systemic hypertension are risk factors for decline in lung function.

Authors:  Catherine H Miele; Matthew R Grigsby; Trishul Siddharthan; Robert H Gilman; J Jaime Miranda; Antonio Bernabe-Ortiz; Robert A Wise; William Checkley
Journal:  Thorax       Date:  2018-07-30       Impact factor: 9.139

2.  Free Urinary Desmosine and Isodesmosine as COPD Biomarkers: The Relevance of Confounding Factors.

Authors:  Sara Ongay; Marijke Sikma; Peter Horvatovich; Jos Hermans; Bruce E Miller; Nick H T Ten Hacken; Rainer Bischoff
Journal:  Chronic Obstr Pulm Dis       Date:  2016-03-01

Review 3.  The diagnosis of chronic obstructive pulmonary disease.

Authors:  Rainer Burkhardt; Wulf Pankow
Journal:  Dtsch Arztebl Int       Date:  2014-12-05       Impact factor: 5.594

4.  Increased Decline in Pulmonary Function Among Employees in Norwegian Smelters Reporting Work-Related Asthma-Like Symptoms.

Authors:  Vidar Søyseth; Helle Laier Johnsen; Paul K Henneberger; Johny Kongerud
Journal:  J Occup Environ Med       Date:  2015-09       Impact factor: 2.162

5.  Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD.

Authors:  Donald P Tashkin; Ning Li; David Halpin; Eric Kleerup; Marc Decramer; Bartolome Celli; Robert Elashoff
Journal:  Respir Med       Date:  2013-08-22       Impact factor: 3.415

6.  The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods.

Authors:  Peter Kardos; Claus Vogelmeier; Roland Buhl; Carl-Peter Criée; Heinrich Worth
Journal:  BMC Pulm Med       Date:  2015-01-12       Impact factor: 3.317

7.  Efficacy of a multifactorial intervention on therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled trial.

Authors:  José Leiva-Fernández; Francisca Leiva-Fernández; Antonio García-Ruiz; Daniel Prados-Torres; Pilar Barnestein-Fonseca
Journal:  BMC Pulm Med       Date:  2014-04-25       Impact factor: 3.317

8.  Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.

Authors:  Job Fm van Boven; Janwillem Wh Kocks; Maarten J Postma
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-19

9.  Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting.

Authors:  Hannah R Whittaker; Hana Müllerova; Deborah Jarvis; Neil C Barnes; Paul W Jones; Chris H Compton; Steven J Kiddle; Jennifer K Quint
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-23

10.  Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.

Authors:  Jiska B Snoeck-Stroband; Therese S Lapperre; Peter J Sterk; Pieter S Hiemstra; Henk A Thiadens; H Marike Boezen; Nick H T Ten Hacken; Huib A M Kerstjens; Dirkje S Postma; Wim Timens; Jacob K Sont
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.